Literature DB >> 21620067

Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases.

U Baccarani1, G L Adani, F Bragantini, A Londero, C Comuzzi, A Rossetto, D Lorenzin, V Bresadola, A Risaliti, F Pea, P Toniutto, A Donini, D De Anna, F Bresadola, M Tavio, P Viale.   

Abstract

Human immunodeficiency virus (HIV) positivity is no longer a contraindication for orthotopic liver transplantation (OLT) due to the efficacy of antiretroviral therapy. The aim of this study was to compare OLT among HIV-positive and HIV-negative cohorts; the results were also stratified for hepatitis C virus (HCV) coinfection. Between 2004 and 2009, all HIV-infected patients undergoing OLT from heart-beating deceased donors (n=27) were compared with an HIV-negative cohort (n = 27). The pure HCV infection rate was similar between HIV-positive and HIV-negative subjects (63% each). HIV-positive recipients were younger (P=.013). The CD4 count for HIV-positive subjects was 376 ± 156 at transplantation. The mean model for end-stage liver disease (MELD) score at transplantation was 15 ± 7 in both groups (P=.92). No differences were observed for donor age (P=.72) or time on the waiting list (P=.56). The median follow-up was 26 (range, 1-64) and 27 months (range, 1-48) for HIV and non-HIV recipients, respectively (P=.85). The estimated 1-, 3-, and 5-year patient and graft survival rates were 88%, 83%, and 83% versus 100%, 73%, and 73% (P=.95), and 92%, 87%, and 87% versus 95%, 88%, and 88% (P=.59) for HIV and non-HIV cases, respectively. HIV/HCV-coinfected patients were younger, namely 47 (range, 40-53) versus 52 years (range, 37-68; P=.003), and displayed lower MELD scores at transplantation compared with HCV-mono-infected patients 10 (range, 7-19) versus 17 (range, 8-30) (P=.008). For HIV/HCV-coinfected and HCV-mono-infected cases the estimated 1-, 3-, and 5-year patients and graft survival rates were respectively 93%, 76%, and 76% versus 100%, 70%, and 60% (P=.99) and 93%, 84%, and 84% versus 100%, 70%, and 60% (P=.64), respectively. No difference was observed in the histological severity of HCV recurrence. In conclusion, under specific, well-determined conditions, OLT can be a safe, efficacious procedure in HIV patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21620067     DOI: 10.1016/j.transproceed.2011.01.124

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Liver transplantation trends in the HIV population.

Authors:  Nyingi M Kemmer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2011-08-30       Impact factor: 3.199

2.  Organ Transplantation and HIV Progress or Success? A Review of Current Status.

Authors:  Alan Taege
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

3.  Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls.

Authors:  Michelle E Roland; Burc Barin; Shirish Huprikar; Barbara Murphy; Douglas W Hanto; Emily Blumberg; Kim Olthoff; David Simon; William D Hardy; George Beatty; Peter G Stock
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.